AI platform integrated into ultrasound machines to assist in real-time prenatal screening of congenital heart disease.
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Series A French BrightHeart raised an €11 million Series A co-led by Odyssée Venture and GO Capital to bring its AI for fetal cardiac screening to the US, backed by five FDA clearances. | $12.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.